CIK 0001754068 · Non-accelerated filer<br>Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 831971007
- Phone
- 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-18 | AKKARAJU SRINIVAS Director | Purchase | +479,847 | $10.42 | $5.0M | 1,979,847 |
| 2025-11-03 | Gall Matthew Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +235,000 | 235,000 | ||
| 2025-04-10 | Hagen Brett R Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +50,262 | 50,262 | ||
| 2025-04-10 | AKKARAJU SRINIVAS Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-04-10 | Jovan-Embiricos Morana Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-04-10 | PATEL SAMIR CHANDRAKANT Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-04-10 | Ferrara Napoleone Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-04-10 | Dybbs Michael Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-04-10 | Oxtoby Andrew See Remarks | Grant or award · Stock Option (Right to Buy) | +287,000 | 287,000 | ||
| 2025-04-10 | ADAMIS ANTHONY P Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-04-10 | Feinsod Matthew Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +70,551 | 70,551 | ||
| 2025-04-10 | Feinsod Matthew Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +101,000 | 101,000 | ||
| 2025-04-10 | PATTERSON LEONE D Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-04-10 | Hallal David Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-03-26 | Hagen Brett R Chief Accounting Officer | Sale | −907 | $8.97 | $8K | 1,925 |
| 2025-03-18 | Ferrara Napoleone Director | Grant or award | +504,000 | 504,000 | ||
| 2025-03-18 | PATEL SAMIR CHANDRAKANT Director | Grant or award | +252,000 | 252,000 | ||
| 2025-03-18 | PATEL SAMIR CHANDRAKANT Director | Grant or award | +100,800 | 100,800 | ||
| 2025-03-18 | PATEL SAMIR CHANDRAKANT Director | Grant or award · Stock Option (right to buy) | +105,913 | 105,913 | ||
| 2025-03-18 | Feinsod Matthew Chief Medical Officer | Grant or award | +4,030 | 4,030 |
Page 2 of 7 · 122 trades